Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non-Small-Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 696-702

  Massabeau, Carole ^a   Rouquette, Isabelle ^b   Lauwers Cances, Valérie ^b   Mazières, Julien ^c   Bachaud, Jean Marc ^a   Armand, Jean Pierre ^a   Delisle, Marie Bernadette ^b   Favre, Gilles ^a   Toulas, Christine ^a   Cohen Jonathan Moyal, Elizabeth ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Basic fibroblast growth factor; Chemotherapy; FGF 2; Integrins; Lung cancer; Radiotherapy

Indexed keywords

ANGIOPOIETIN-2; BASIC FIBROBLAST GROWTH FACTOR; CHEMORADIOTHERAPY; CLINICAL OUTCOME; CO-EXPRESSION; COMPUTED TOMOGRAPHY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; EVALUATION CRITERIA; EXPRESSION PROFILE; FGF-2; HAZARD RATIO; IMMUNOHISTOCHEMISTRY; INTEGRINS; LOCAL CONTROL; LOCAL RECURRENCE; LUNG CANCER; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS; RADIORESISTANCE; RANK TEST; SOLID TUMORS; SYNDECAN-1;

BIOACTIVITY; BIOLOGICAL ORGANS; BIOPSY; CELL CULTURE; CELL MEMBRANES; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DRUG PRODUCTS; FIBROBLASTS; GLYCOPROTEINS; ONCOLOGY; PATHOLOGY; PATIENT MONITORING; PEPTIDES; RADIOTHERAPY; TOMOGRAPHY;

TUMORS;

ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BETA3 INTEGRIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; SYNDECAN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; ANGIOPOIETIN-2; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTEGRIN BETA3; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; SYNDECAN-1;

EID: 70349546308     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.050     Document Type: Article

References (39)

1. Jett J.R., Scott W.J., Rivera M.P., et al. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 123 (2003) 221S-225S
2. Curran Jr. W.J. Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. Oncology (Williston Park) 17 (2003) 7-14
3. Vokes E.E., Herndon J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20 (2002) 4191-4198
4. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol 23 (2005) 5910-5917
5. Kim S., Kim M., Choi E., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): Randomized phase III trial. J Clin Oncol 25 (2007) 7528
6. Hanna N.H., Neubauer M., Ansari R., et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol 25 (2007) 7512
7. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
8. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
9. Seve P., Lai R., Ding K., et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 13 (2007) 994-999
10. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
11. Milas L., Mason K.A., and Ang K.K. Epidermal growth factor receptor and its inhibition in radiotherapy: In vivo findings. Int J Radiat Biol 79 (2003) 539-545
12. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22 (2003) 5855-5865
13. Fuks Z., Persaud R.S., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54 (1994) 2582-2590
14. Delmas C., Heliez C., Cohen-Jonathan E., et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100 (2002) 43-48
15. Ader I., Toulas C., Dalenc F., et al. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21 (2002) 5998-6006
16. 2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 57 (1997) 1364-1370
17. Shah L., Walter K.L., Borczuk A.C., et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101 (2004) 1632-1638
18. Ader I., Muller C., Bonnet J., et al. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene 21 (2002) 6471-6479
19. Ader I., Delmas C., Bonnet J., et al. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene 22 (2003) 8861-8869
20. Skuli N., Monferran S., Delmas C., et al. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res 66 (2006) 482-489
21. Skuli N., Monferran S., Delmas C., et al. alphavbeta3/alphavbeta5 integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69 (2009) 3308-3316
22. Takanami I., Tanaka F., Hashizume T., et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers. Eur J Cancer 32A (1996) 1504-1509
23. Tanaka F., Ishikawa S., Yanagihara K., et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62 (2002) 7124-7129
24. Kuhn H., Konrad J., Holtz S., et al. Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer 54 (2006) 149-153
25. Monferran S., Skuli N., Delmas C., et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer 123 (2008) 357-364
26. Albert J.M., Cao C., Geng L., et al. Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65 (2006) 1536-1543
27. Senan S., De Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
28. Beasley M.B., Brambilla E., and Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40 (2005) 90-97
29. Zhou X.H., Obuchowski N.A., and McClish D.K. Sample size calculation. In: Balding D.J., Bloomfield P., and Cressie N.A.C. (Eds). Statistical methods in diagnosis medicine (2002), John Wiley & Sons, New York 195-221
30. Gruber G., Hess J., Stiefel C., et al. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer 92 (2005) 41-46
31. Sahni A., and Francis C.W. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 104 (2004) 3635-3641
32. Volm M., Koomagi R., Mattern J., et al. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 33 (1997) 691-693
33. Anttonen A., Heikkila P., Kajanti M., et al. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32 (2001) 297-305
34. Toyoshima E., Ohsaki Y., Nishigaki Y., et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung Cancer 31 (2001) 193-202
35. Sloan E.K., Pouliot N., Stanley K.L., et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8 (2006) R20
36. Hieken T.J., Ronan S.G., Farolan M., et al. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85 (1999) 375-382
37. Duensing S., Grosse J., and Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 15 (1995) 2331-2333
38. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
39. Delmas C., End D., Rochaix P., et al. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 9 (2003) 6062-6068